{"id":45272,"date":"2022-06-20T17:01:49","date_gmt":"2022-06-20T15:01:49","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/astorg-acquires-majority-interest-in-avania\/"},"modified":"2022-06-20T17:01:49","modified_gmt":"2022-06-20T15:01:49","slug":"astorg-acquires-majority-interest-in-avania","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/astorg-acquires-majority-interest-in-avania\/","title":{"rendered":"Astorg Acquires Majority Interest in Avania"},"content":{"rendered":"
\n

\nPartners with existing ownership to accelerate growth<\/i><\/b>\n<\/p>\n

BILTHOVEN, Netherlands–(BUSINESS WIRE)–Avania<\/a>, the preeminent, full-service global MedTech contract research organization (\u201cCRO\u201d), today announced that Astorg<\/a> has acquired a majority stake in the company. Astorg, together with Kester Capital<\/a> (\u201cKester\u201d) \u2014 a current investor who intends to retain a minority stake \u2014 will actively support management\u2019s plans to advance Avania\u2019s development as a MedTech solution provider.\n<\/p>\n

<\/a><\/p>\n

\nHeadquartered in the Netherlands, Avania was formed in March 2020 from the combination of five complementary businesses and started a successful journey to establish a fully integrated platform to serve sponsors worldwide in advancing medical technology products from early development to post-market \u2014 ensuring customized, scalable solutions that optimize efficiencies and streamline the advancement of medical technology.\n<\/p>\n

\nAstorg brings an impressive global network of relationships in the MedTech space which will strengthen Avania\u2019s pipeline and broaden its customer base while the capital access will help accelerate its growth, both organically and via acquisitions.\n<\/p>\n

\n\u201cThe platform we have built has positioned us ahead of our competition in the MedTech CRO space, and this deal will bring additional investment to strengthen our infrastructure, capital for acquisitions, and added support as we continue to grow Avania into the clear market leader,\u201d said Sapna Hornyak<\/a>, president and CEO of Avania. \u201cThe largest CROs do not have the specialization that we bring, and the regional niche providers do not have the scale and reach of Avania. This unique positioning, along with the continued changes to the MedTech regulatory landscape, will allow us to push ourselves to the next era of growth.\u201d\n<\/p>\n

\n\u201c<\/b>We are extremely pleased to partner with Sapna and her team, as well as Kester, on this transaction,\u201d said Managing Partner of Astorg Mid-Cap Edouard Pillot<\/a>. \u201cBeing one of the global leaders in a profitable and fast-growing niche market, Avania squarely fits with Astorg\u2019s investment criteria, and we are delighted to have Avania as our first Mid-Cap Healthcare deal, sitting within Astorg\u2019s broader healthcare portfolio.\u201d\n<\/p>\n

\nAbout Avania<\/b>\n<\/p>\n

\nAvania<\/a> is a leading, global full-service contract research organization focused on the management of clinical studies for medical technology, IVDs, biologics, and device-drug combination products internationally. Avania supports products from the first-in-human phase through the post-market phase with the same customized approach. When you need to advance your medical technology, it takes Avania. Avania\u2019s vision is to be your trusted global partner in the evolution of your medical technology from innovation to commercialization to improving patient health and well-being.\n<\/p>\n

\nAbout Astorg<\/b>\n<\/p>\n

\nAstorg<\/a> is a leading private equity firm with over \u20ac17 billion of assets under management. We work with entrepreneurs and management teams to acquire market-leading global companies headquartered in Europe or the US, providing them with the strategic guidance, governance, and capital they need to achieve their growth goals. Astorg enjoys a distinct entrepreneurial culture, a long-term shareholder perspective, and a lean decision-making body. We have valuable industry expertise in healthcare, software, business-to-business professional services and technology-based industrial companies. Astorg has offices in London, Paris, New York, Frankfurt, Milan and Luxembourg.\n<\/p>\n

\nAbout Kester Capital<\/b>\n<\/p>\n

\nKester Capital<\/a> is a primary buy-out specialist. Kester focuses on the healthcare, data & information and technology sectors, targeting businesses that require capital in order to unlock their potential.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nLindsey Langemeier
\n
SCORR Marketing
\n
+1 402-405-4269
\n
lindsey@scorrmarketing.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Partners with existing ownership to accelerate growth BILTHOVEN, Netherlands–(BUSINESS WIRE)–Avania, the preeminent, full-service global MedTech contract research organization (\u201cCRO\u201d), today announced that Astorg has acquired a majority stake in the company. Astorg, together with Kester Capital (\u201cKester\u201d) \u2014 a current investor who intends to retain a minority stake \u2014 will actively support management\u2019s plans to … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":["entry","post","publish","author-business","post-45272","format-standard","category-industry"],"yoast_head":"\nAstorg Acquires Majority Interest in Avania - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/astorg-acquires-majority-interest-in-avania\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Astorg Acquires Majority Interest in Avania - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Partners with existing ownership to accelerate growth BILTHOVEN, Netherlands–(BUSINESS WIRE)–Avania, the preeminent, full-service global MedTech contract research organization (\u201cCRO\u201d), today announced that Astorg has acquired a majority stake in the company. Astorg, together with Kester Capital (\u201cKester\u201d) \u2014 a current investor who intends to retain a minority stake \u2014 will actively support management\u2019s plans to ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/astorg-acquires-majority-interest-in-avania\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-20T15:01:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220620005109\/en\/1490899\/21\/Avania_Logo_RGB.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/astorg-acquires-majority-interest-in-avania\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/astorg-acquires-majority-interest-in-avania\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Astorg Acquires Majority Interest in Avania\",\"datePublished\":\"2022-06-20T15:01:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/astorg-acquires-majority-interest-in-avania\\\/\"},\"wordCount\":549,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/astorg-acquires-majority-interest-in-avania\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220620005109\\\/en\\\/1490899\\\/21\\\/Avania_Logo_RGB.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/astorg-acquires-majority-interest-in-avania\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/astorg-acquires-majority-interest-in-avania\\\/\",\"name\":\"Astorg Acquires Majority Interest in Avania - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/astorg-acquires-majority-interest-in-avania\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/astorg-acquires-majority-interest-in-avania\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220620005109\\\/en\\\/1490899\\\/21\\\/Avania_Logo_RGB.jpg\",\"datePublished\":\"2022-06-20T15:01:49+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/astorg-acquires-majority-interest-in-avania\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/astorg-acquires-majority-interest-in-avania\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/astorg-acquires-majority-interest-in-avania\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220620005109\\\/en\\\/1490899\\\/21\\\/Avania_Logo_RGB.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220620005109\\\/en\\\/1490899\\\/21\\\/Avania_Logo_RGB.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/astorg-acquires-majority-interest-in-avania\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Astorg Acquires Majority Interest in Avania\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Astorg Acquires Majority Interest in Avania - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/astorg-acquires-majority-interest-in-avania\/","og_locale":"en_US","og_type":"article","og_title":"Astorg Acquires Majority Interest in Avania - Pharma Trend","og_description":"Partners with existing ownership to accelerate growth BILTHOVEN, Netherlands–(BUSINESS WIRE)–Avania, the preeminent, full-service global MedTech contract research organization (\u201cCRO\u201d), today announced that Astorg has acquired a majority stake in the company. Astorg, together with Kester Capital (\u201cKester\u201d) \u2014 a current investor who intends to retain a minority stake \u2014 will actively support management\u2019s plans to ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/astorg-acquires-majority-interest-in-avania\/","og_site_name":"Pharma Trend","article_published_time":"2022-06-20T15:01:49+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220620005109\/en\/1490899\/21\/Avania_Logo_RGB.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/astorg-acquires-majority-interest-in-avania\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/astorg-acquires-majority-interest-in-avania\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Astorg Acquires Majority Interest in Avania","datePublished":"2022-06-20T15:01:49+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/astorg-acquires-majority-interest-in-avania\/"},"wordCount":549,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/astorg-acquires-majority-interest-in-avania\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220620005109\/en\/1490899\/21\/Avania_Logo_RGB.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/astorg-acquires-majority-interest-in-avania\/","url":"https:\/\/pharma-trend.com\/en\/astorg-acquires-majority-interest-in-avania\/","name":"Astorg Acquires Majority Interest in Avania - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/astorg-acquires-majority-interest-in-avania\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/astorg-acquires-majority-interest-in-avania\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220620005109\/en\/1490899\/21\/Avania_Logo_RGB.jpg","datePublished":"2022-06-20T15:01:49+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/astorg-acquires-majority-interest-in-avania\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/astorg-acquires-majority-interest-in-avania\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/astorg-acquires-majority-interest-in-avania\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220620005109\/en\/1490899\/21\/Avania_Logo_RGB.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220620005109\/en\/1490899\/21\/Avania_Logo_RGB.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/astorg-acquires-majority-interest-in-avania\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Astorg Acquires Majority Interest in Avania"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/45272","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=45272"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/45272\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=45272"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=45272"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=45272"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}